Venus Concept Inc. Stock price

Equities

VERO

US92332W2044

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.691 USD -4.03% Intraday chart for Venus Concept Inc. +7.13% -41.44%
Sales 2023 * 80.66M Sales 2024 * 86.33M Capitalization 4.39M
Net income 2023 * -33M Net income 2024 * -23M EV / Sales 2023 * 0.05 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.05 x
P/E ratio 2023 *
-0.11 x
P/E ratio 2024 *
-0.2 x
Employees 384
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.22%
More Fundamentals * Assessed data
Dynamic Chart
Venus Concept Continues Listing on Nasdaq, Gets May Deadline to Meet Equity Requirement MT
Certain Options of Venus Concept Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024. CI
Venus Concept Inc. announced that it has received CAD 1.095782 million in funding CI
Venus Concept Inc. announced that it expects to receive CAD 1.095782 million in funding CI
Madryn Asset Provides Information to the Shareholders CI
Venus Concept Announces Review of Strategic Alternatives CI
Venus Concept Inc. announced that it has received CAD 2 million in funding from Essex Woodlands Management, Inc. and another investor CI
Venus Concept Inc. Announces New International Distributors in the United Kingdom and India to Continue Global Growth CI
Transcript : Venus Concept Inc., Q3 2023 Earnings Call, Nov 14, 2023
Venus Concept Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (VERO) VENUS CONCEPT Reports Q3 Revenue $17.6M, vs. Street Est of $17.5M MT
Earnings Flash (VERO) VENUS CONCEPT Posts Q3 Revenue $17.6M, vs. Street Est of $17.5M MT
Venus Concept Inc. Provides Earnings Guidance for the Twelve Months Ending December 31, 2023 CI
Venus Concept Inc. Launches Venus Versa Pro, its New Multi-Application Platform for Face and Body Treatments CI
Madryn Asset Management Engages in Discussions with Venus Concept CI
More news
1 day-4.03%
1 week+7.13%
Current month-18.71%
1 month-20.57%
3 months-42.42%
6 months-65.28%
Current year-41.44%
More quotes
1 week
0.68
Extreme 0.68
0.77
1 month
0.60
Extreme 0.6015
0.89
Current year
0.60
Extreme 0.6015
2.22
1 year
0.60
Extreme 0.6015
4.70
3 years
0.60
Extreme 0.6015
50.55
5 years
0.60
Extreme 0.6015
135.00
10 years
0.60
Extreme 0.6015
135.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 22-10-01
Director of Finance/CFO 63 17-08-31
President 49 22-10-16
Members of the board TitleAgeSince
Director/Board Member 66 18-06-30
Director/Board Member 51 19-10-31
Director/Board Member 67 15-07-31
More insiders
Date Price Change Volume
24-03-28 0.691 -4.03% 36,718
24-03-27 0.72 +2.11% 22,670
24-03-26 0.7051 -2.07% 26,197
24-03-25 0.72 +4.35% 10,212
24-03-22 0.69 +6.98% 12,553

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Venus Concept Inc. is a global medical aesthetic technology company. The Company has a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches in over 60 countries and 14 direct markets. The Company's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. The Company's systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry's traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company's hair loss treatment solutions include the ARTAS Solution and the NeoGraft Solution.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.691
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Venus Concept Inc. - Nasdaq